Highlights
The global Cancer Immunotherapy Drug Discovery Outsourcing market was valued at US$ 1119.1 million in 2022 and is anticipated to reach US$ 2057.2 million by 2029, witnessing a CAGR of 10.7% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Cancer Immunotherapy Drug Discovery Outsourcing is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Cancer Immunotherapy Drug Discovery Outsourcing is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Cancer Immunotherapy Drug Discovery Outsourcing in Lung is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Cancer Immunotherapy Drug Discovery Outsourcing include Aquila BioMedical, BPS Bioscience, Inc., Celentyx Ltd, Crown Bioscience, Inc., DiscoverX Corporation, Explicyte, Genscript Biotech Corporation, HD Biosciences Co. and Horizon Discovery Group PLC, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cancer Immunotherapy Drug Discovery Outsourcing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Immunotherapy Drug Discovery Outsourcing.
The Cancer Immunotherapy Drug Discovery Outsourcing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cancer Immunotherapy Drug Discovery Outsourcing market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Immunotherapy Drug Discovery Outsourcing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Aquila BioMedical
BPS Bioscience, Inc.
Celentyx Ltd
Crown Bioscience, Inc.
DiscoverX Corporation
Explicyte
Genscript Biotech Corporation
HD Biosciences Co.
Horizon Discovery Group PLC
ImmunXperts SA
Molecular Imaging, Inc.
Promega Corporation,Personalis, Inc.
STC Biologics
Segment by Type
By Drug Type
By Cancer Type
Segment by Application
Lung
Breast
Colorectal
Melanoma
Prostate
Head and Neck
Ovarian
Pancreatic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Immunotherapy Drug Discovery Outsourcing companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis By Drug Type
1.2.1 Global Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Size Growth Rate By Drug Type: 2018 VS 2022 VS 2029
1.2.2 By Drug Type
1.2.3 By Cancer Type
1.3 麻豆原创 by Application
1.3.1 Global Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Lung
1.3.3 Breast
1.3.4 Colorectal
1.3.5 Melanoma
1.3.6 Prostate
1.3.7 Head and Neck
1.3.8 Ovarian
1.3.9 Pancreatic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Perspective (2018-2029)
2.2 Cancer Immunotherapy Drug Discovery Outsourcing Growth Trends by Region
2.2.1 Global Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Cancer Immunotherapy Drug Discovery Outsourcing Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Cancer Immunotherapy Drug Discovery Outsourcing Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Dynamics
2.3.1 Cancer Immunotherapy Drug Discovery Outsourcing Industry Trends
2.3.2 Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Drivers
2.3.3 Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Challenges
2.3.4 Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Immunotherapy Drug Discovery Outsourcing Players by Revenue
3.1.1 Global Top Cancer Immunotherapy Drug Discovery Outsourcing Players by Revenue (2018-2023)
3.1.2 Global Cancer Immunotherapy Drug Discovery Outsourcing Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cancer Immunotherapy Drug Discovery Outsourcing Revenue
3.4 Global Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Concentration Ratio
3.4.1 Global Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Immunotherapy Drug Discovery Outsourcing Revenue in 2022
3.5 Cancer Immunotherapy Drug Discovery Outsourcing Key Players Head office and Area Served
3.6 Key Players Cancer Immunotherapy Drug Discovery Outsourcing Product Solution and Service
3.7 Date of Enter into Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Immunotherapy Drug Discovery Outsourcing Breakdown Data by Type
4.1 Global Cancer Immunotherapy Drug Discovery Outsourcing Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Cancer Immunotherapy Drug Discovery Outsourcing Forecasted 麻豆原创 Size by Type (2024-2029)
5 Cancer Immunotherapy Drug Discovery Outsourcing Breakdown Data by Application
5.1 Global Cancer Immunotherapy Drug Discovery Outsourcing Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Cancer Immunotherapy Drug Discovery Outsourcing Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Size (2018-2029)
6.2 North America Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Size by Country (2018-2023)
6.4 North America Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Size (2018-2029)
7.2 Europe Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Size by Country (2018-2023)
7.4 Europe Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Size (2018-2029)
9.2 Latin America Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Cancer Immunotherapy Drug Discovery Outsourcing 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Aquila BioMedical
11.1.1 Aquila BioMedical Company Detail
11.1.2 Aquila BioMedical Business Overview
11.1.3 Aquila BioMedical Cancer Immunotherapy Drug Discovery Outsourcing Introduction
11.1.4 Aquila BioMedical Revenue in Cancer Immunotherapy Drug Discovery Outsourcing Business (2018-2023)
11.1.5 Aquila BioMedical Recent Development
11.2 BPS Bioscience, Inc.
11.2.1 BPS Bioscience, Inc. Company Detail
11.2.2 BPS Bioscience, Inc. Business Overview
11.2.3 BPS Bioscience, Inc. Cancer Immunotherapy Drug Discovery Outsourcing Introduction
11.2.4 BPS Bioscience, Inc. Revenue in Cancer Immunotherapy Drug Discovery Outsourcing Business (2018-2023)
11.2.5 BPS Bioscience, Inc. Recent Development
11.3 Celentyx Ltd
11.3.1 Celentyx Ltd Company Detail
11.3.2 Celentyx Ltd Business Overview
11.3.3 Celentyx Ltd Cancer Immunotherapy Drug Discovery Outsourcing Introduction
11.3.4 Celentyx Ltd Revenue in Cancer Immunotherapy Drug Discovery Outsourcing Business (2018-2023)
11.3.5 Celentyx Ltd Recent Development
11.4 Crown Bioscience, Inc.
11.4.1 Crown Bioscience, Inc. Company Detail
11.4.2 Crown Bioscience, Inc. Business Overview
11.4.3 Crown Bioscience, Inc. Cancer Immunotherapy Drug Discovery Outsourcing Introduction
11.4.4 Crown Bioscience, Inc. Revenue in Cancer Immunotherapy Drug Discovery Outsourcing Business (2018-2023)
11.4.5 Crown Bioscience, Inc. Recent Development
11.5 DiscoverX Corporation
11.5.1 DiscoverX Corporation Company Detail
11.5.2 DiscoverX Corporation Business Overview
11.5.3 DiscoverX Corporation Cancer Immunotherapy Drug Discovery Outsourcing Introduction
11.5.4 DiscoverX Corporation Revenue in Cancer Immunotherapy Drug Discovery Outsourcing Business (2018-2023)
11.5.5 DiscoverX Corporation Recent Development
11.6 Explicyte
11.6.1 Explicyte Company Detail
11.6.2 Explicyte Business Overview
11.6.3 Explicyte Cancer Immunotherapy Drug Discovery Outsourcing Introduction
11.6.4 Explicyte Revenue in Cancer Immunotherapy Drug Discovery Outsourcing Business (2018-2023)
11.6.5 Explicyte Recent Development
11.7 Genscript Biotech Corporation
11.7.1 Genscript Biotech Corporation Company Detail
11.7.2 Genscript Biotech Corporation Business Overview
11.7.3 Genscript Biotech Corporation Cancer Immunotherapy Drug Discovery Outsourcing Introduction
11.7.4 Genscript Biotech Corporation Revenue in Cancer Immunotherapy Drug Discovery Outsourcing Business (2018-2023)
11.7.5 Genscript Biotech Corporation Recent Development
11.8 HD Biosciences Co.
11.8.1 HD Biosciences Co. Company Detail
11.8.2 HD Biosciences Co. Business Overview
11.8.3 HD Biosciences Co. Cancer Immunotherapy Drug Discovery Outsourcing Introduction
11.8.4 HD Biosciences Co. Revenue in Cancer Immunotherapy Drug Discovery Outsourcing Business (2018-2023)
11.8.5 HD Biosciences Co. Recent Development
11.9 Horizon Discovery Group PLC
11.9.1 Horizon Discovery Group PLC Company Detail
11.9.2 Horizon Discovery Group PLC Business Overview
11.9.3 Horizon Discovery Group PLC Cancer Immunotherapy Drug Discovery Outsourcing Introduction
11.9.4 Horizon Discovery Group PLC Revenue in Cancer Immunotherapy Drug Discovery Outsourcing Business (2018-2023)
11.9.5 Horizon Discovery Group PLC Recent Development
11.10 ImmunXperts SA
11.10.1 ImmunXperts SA Company Detail
11.10.2 ImmunXperts SA Business Overview
11.10.3 ImmunXperts SA Cancer Immunotherapy Drug Discovery Outsourcing Introduction
11.10.4 ImmunXperts SA Revenue in Cancer Immunotherapy Drug Discovery Outsourcing Business (2018-2023)
11.10.5 ImmunXperts SA Recent Development
11.11 Molecular Imaging, Inc.
11.11.1 Molecular Imaging, Inc. Company Detail
11.11.2 Molecular Imaging, Inc. Business Overview
11.11.3 Molecular Imaging, Inc. Cancer Immunotherapy Drug Discovery Outsourcing Introduction
11.11.4 Molecular Imaging, Inc. Revenue in Cancer Immunotherapy Drug Discovery Outsourcing Business (2018-2023)
11.11.5 Molecular Imaging, Inc. Recent Development
11.12 Promega Corporation,Personalis, Inc.
11.12.1 Promega Corporation,Personalis, Inc. Company Detail
11.12.2 Promega Corporation,Personalis, Inc. Business Overview
11.12.3 Promega Corporation,Personalis, Inc. Cancer Immunotherapy Drug Discovery Outsourcing Introduction
11.12.4 Promega Corporation,Personalis, Inc. Revenue in Cancer Immunotherapy Drug Discovery Outsourcing Business (2018-2023)
11.12.5 Promega Corporation,Personalis, Inc. Recent Development
11.13 STC Biologics
11.13.1 STC Biologics Company Detail
11.13.2 STC Biologics Business Overview
11.13.3 STC Biologics Cancer Immunotherapy Drug Discovery Outsourcing Introduction
11.13.4 STC Biologics Revenue in Cancer Immunotherapy Drug Discovery Outsourcing Business (2018-2023)
11.13.5 STC Biologics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Aquila BioMedical
BPS Bioscience, Inc.
Celentyx Ltd
Crown Bioscience, Inc.
DiscoverX Corporation
Explicyte
Genscript Biotech Corporation
HD Biosciences Co.
Horizon Discovery Group PLC
ImmunXperts SA
Molecular Imaging, Inc.
Promega Corporation,Personalis, Inc.
STC Biologics
听
听
*If Applicable.